Article
Medicine, General & Internal
Hiddo J. L. Heerspink, Arihiro Kiyosue, David C. Wheeler, Min Lin, Emma Wijkmark, Glenn Carlson, Anne-Kristina Mercier, Magnus Astrand, Sebastian Ueckert, Peter J. Greasley, Phil Ambery
Summary: This study evaluated the efficacy and safety of the ERA zibotentan combined with the SGLT2 inhibitor dapagliflozin in reducing albuminuria and protecting kidney function.
Article
Pharmacology & Pharmacy
Yuanping Wang, Jiahua Li, Jiaqi Yan, Yulin Wang, Yuanyuan Cheng, Zhongqiu Liu, Dawei Wang
Summary: This study aims to evaluate the efficacy and safety of XBP as an adjuvant treatment for patients with CHF. The primary outcome will be the change in the proportion of patients who show a decrease in serum NT-proBNP of more than 30% after treatment. The results may provide solid evidence for XBP as an alternative and complementary treatment measure for CHF patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Health Care Sciences & Services
Patrick Ware, Amika Shah, Heather Joan Ross, Alexander Gordon Logan, Phillip Segal, Joseph Antony Cafazzo, Katarzyna Szacun-Shimizu, Myles Resnick, Tessy Vattaparambil, Emily Seto
Summary: This study aimed to evaluate the impact and experiences of using a telemonitoring system for patients with complex conditions. The results showed improvements in self-care maintenance and physical quality of life for patients with heart failure (HF). However, opinions on telemonitoring varied among patients and healthcare providers depending on the monitored conditions.
JOURNAL OF MEDICAL INTERNET RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Kangjia Du, Junjie Liu, Nannan Tan, Xinyi Huang, Juan Wang, Huihui Zhao, Wei Wang
Summary: This study evaluated the effects of Qishen granules (QSG) on chronic heart failure (CHF) patients. The results showed that QSG further reduced the levels of NT-proBNP and improved other outcomes such as NYHA functional rank, 6MWD, TCM syndrome integral scale, and quality of life in CHF patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Allison Martin, Robert J. Hancox, Catherina L. Chang, Richard Beasley, Jeremy Wrobel, Vanessa McDonald, Claudia C. Dobler, Ian A. Yang, Claude S. Farah, Belinda Cochrane, Graham S. Hillis, Caroline Polak Scowcroft, Ashutosh Aggarwal, Gian Luca Di Tanna, Grace Balicki, Shane Galgey, Christine Jenkins
Summary: This study aims to investigate the safety and benefits of cardioselective beta-blockers in patients with COPD, as well as their impact on reducing mortality and cardiac and respiratory morbidity.
Article
Pharmacology & Pharmacy
Yu Wang, Jiaping Xu, Jiehong Yang, Ling Zhang, Yuanjiang Pan, Liping Dou, Peng Zhou, Yizhou Xu, Chang Li, Yu He, Huifen Zhou, Li Yu, Jingwen Chen, Shuwei Huang, Wei Fu, Haitong Wan
Summary: Chronic heart failure is a common cardiovascular disease with high mortality. Traditional Chinese medicine has been used as complementary treatment for CHF, with Guanxinshutong capsules commonly used for coronary heart disease. However, the effects of GXST as complementary medicine in CHF treatment lack high-quality clinical evidence. This study aims to explore the efficacy and safety of using GXST compared with a placebo for CHF patients with reduced LVEF.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Mengying Cao, Hao Wang, Wenshu Li, Xueli Jiang, Xiaolin Wang, Wei Guo, Pan Gao, Yunzeng Zou
Summary: This study found that serum sFRP2 levels significantly decreased in HF patients with the presence of T2DM, showing negative correlations with various clinical parameters; multiple regression analysis indicated significant associations of FPG, hs-CRP, and LAD with ln(sFRP2); higher serum sFRP2 levels were significantly associated with lower risks of HF in CVD patients.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Agriculture, Multidisciplinary
Behnaz Pourrajab, Nasim Naderi, Leila Janani, Marjan Hajahmadi, Vahid Mofid, Afsaneh Dehnad, Mohammad Hassan Sohouli, Sharieh Hosseini, Farzad Shidfar
Summary: This study investigated the effects of probiotic yogurt on patients with chronic heart failure. The results showed that probiotic yogurt can improve the inflammatory status of patients by increasing the levels of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK). However, no significant differences were found in other indices.
JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE
(2022)
Article
Cardiac & Cardiovascular Systems
Anna Norhammar, Johan Bodegard, Marc Vanderheyden, Navdeep Tangri, Avraham Karasik, Aldo Pietro Maggioni, Kari Anne Sveen, Tiago Taveira-Gomes, Manuel Botana, Lukas Hunziker, Marcus Thuresson, Amitava Banerjee, Johan Sundstrom, Andreas Bollmann
Summary: The CaReMe HF study collected individual level data from digital healthcare systems in 11 countries to estimate the prevalence, clinical outcomes, and costs of HF. The study found that 1-2% of the contemporary adult population has HF, and these individuals are at significant risk of adverse outcomes and associated costs.
Article
Rehabilitation
Rachel E. Ellis, Karen J. Dodd, Anne E. Holland, Kwang Lim, Mark Tacey, Nora Shields
Summary: The study aimed to determine the effectiveness of eccentric exercise in improving function and quality of life in heart failure patients. The results showed no significant superiority of eccentric exercise over concentric exercise or a waitlist control group.
DISABILITY AND REHABILITATION
(2022)
Article
Medicine, General & Internal
Minakshi Dhar, Kartik Mittal, Ashwin Parchani, Manu Sharma, Yogesh Bahurupi, Sanjay Kalra, Nowneet Kumar Bhat
Summary: Heart failure is a common disease in the geriatric population, and current treatment options are limited. Testosterone therapy is considered as a potential treatment with beneficial effects. This study aims to investigate the effects of testosterone gel on functional capacity, frailty, and quality of life in males with chronic stable heart failure. The study will recruit 986 participants and utilize an open-label, parallel design randomized controlled trial.
Article
Cardiac & Cardiovascular Systems
Ana Garcia-Alvarez, Isabel Blanco, Ines Garcia-Lunar, Paloma J. Jorda, Juan Rodriguez-Arias, Leticia Fernandez-Friera, Isabel Zegri, Jorge Nuche, Manuel Gomez-Bueno, Susanna Prat, Sandra Pujadas, Eduard D. Sole-Gonzalez, Maria Garcia-Cossio, Mercedes Rivas, Estefania Torrecilla, Daniel Pereda, Javier Sanchez, Pablo Garcia-Pavia, Javier Segovia-Cubero, Juan F. Delgado, Sonia Mirabet, Valentin A. Fuster, Joan Barbera, Borja Ibanez
Summary: This study aimed to evaluate the efficacy of the selective beta 3 adrenoreceptor agonist mirabegron in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH). The results showed that mirabegron treatment did not reduce pulmonary vascular resistance in CpcPH patients, but significantly improved right ventricular ejection fraction.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Gerhard Poelzl, Johann Altenberger, Josep Comin-Colet, Juan F. Delgado, Francesco Fedele, Martin Jesus Garcia-Gonzalez, Finn Gustafsson, Josep Masip, Zoltan Papp, Stefan Stoerk, Hanno Ulmer, Sarah Maier, Bojan Vrtovec, Gerhard Wikstrom, Endre Zima, Axel Bauer, LeoDOR Investigators
Summary: The LeoDOR trial aimed to investigate the efficacy and safety of intermittent levosimendan therapy in patients with acute heart failure after hospitalization. The results showed that intermittent levosimendan therapy did not improve post-hospitalization clinical stability in patients recently hospitalized with reduced left ventricular ejection fraction.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Multidisciplinary Sciences
Maria F. Paton, John Gierula, Judith E. Lowry, David A. Cairns, Kieran Bose Rosling, Charlotte A. Cole, Melanie McGinlay, Sam Straw, Rowena Byrom, Richard M. Cubbon, Mark T. Kearney, Klaus K. Witte
Summary: The study aimed to compare personalized pacemaker reprogramming with usual care on echocardiographic and patient-oriented outcomes. Results showed that personalized programming reduced RV pacing, improved LV function and size, and extended battery longevity, with no impact on quality of life.
Article
Medicine, General & Internal
Yibing Gao, Ying Gao, Rong Zhu, Xiao Tan
Summary: The study aims to evaluate the efficacy and safety of Shenfu injection combined with furosemide in the treatment of chronic heart failure in patients with coronary heart disease through a randomized controlled trial.
Article
Cardiac & Cardiovascular Systems
Wouter Ouwerkerk, Jasper Tromp, John G. F. Cleland, Christiane E. Angermann, Ulf Dahlstrom, Georg Ertl, Mahmoud Hassanein, Sergio Perrone, Mathieu Ghadanfar, Anja Schweizer, Achim Obergfell, Kenneth Dickstein, Gerasimos Filippatos, Sean P. Collins, Carolyn S. P. Lam
Summary: In patients with acute heart failure, delayed administration of intravenous diuretics was not significantly associated with in-hospital mortality, but was associated with increased 30-day mortality, especially in high-risk patients. This association was independent of left ventricular ejection fraction or geographic region.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Jawad H. Butt, Wasyla Ibrahim, Pooja Dewan, Akshay S. Desai, Lars Kober, Margaret F. Prescott, Martin P. Lefkowitz, Jean L. Rouleau, Scott D. Solomon, Michael R. Zile, Milton Packer, Pardeep S. Jhund, John J. V. McMurray
Summary: This study examined the relationship between ucGMP/BNP ratio and clinical outcomes, as well as the impact of Sacubitril/valsartan on ucGMP/BNP ratio and clinical outcomes. The study found that higher ucGMP/BNP ratio was associated with better outcomes, and Sacubitril/valsartan increased ucGMP/BNP ratio compared to enalapril, with consistent effects on clinical outcomes regardless of baseline ucGMP/BNP ratio.
CIRCULATION-HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Zachary I. Whinnett, Matthew J. Shun-Shin, Mark Tanner, Paul Foley, Badri Chandrasekaran, Philip Moore, Shaumik Adhya, Norman Qureshi, Amal Muthumala, Rebecca Lane, Aldo Rinaldi, Sharad Agarwal, Francisco Leyva, Jonathan Behar, Sukh Bassi, Andre Ng, Paul Scott, Rachana Prasad, Jon Swinburn, Joseph Tomson, Amarjit Sethi, Jaymin Shah, Phang Boon Lim, Andreas Kyriacou, Dewi Thomas, Jenny Chuen, Ravi Kamdar, Prapa Kanagaratnam, Myril Mariveles, Leah Burden, Katherine March, James P. Howard, Ahran Arnold, Pugazhendhi Vijayaraman, Berthold Stegemann, Nicholas Johnson, Emanuela Falaschetti, Darrel P. Francis, John G. F. Cleland, Daniel Keene
Summary: The study evaluated the effects of optimized His bundle pacing compared to no-pacing in patients with heart failure. It was found that His bundle pacing significantly improved quality of life and was preferred by the majority of patients. However, it did not show any significant changes in peak oxygen uptake or left ventricular ejection fraction.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Joao Pedro Ferreirra, John G. Cleland, Nicolas Girerd, Patrick Rossignol, Pierpaolo Pellicori, Franco Cosmi, Beatrice Mariottoni, Arantxa Gonzalez, Javier Diez, Scott D. Solomon, Brian Claggett, Marc A. Pfeffer, Bertram Pitt, Johannes Petutschnigg, Burkert Pieske, Frank Edelmann, Faiez Zannad
Summary: Spironolactone reduces serum concentrations of PICP in patients with HFpEF, indicating its anti-fibrotic effect.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Stephen J. H. Dobbin, Li Shen, Mark C. Petrie, Milton Packer, Scott D. Solomon, John J. V. McMurray, Ninian N. N. Lang, Pardeep S. Jhund
Summary: This study examined the association between cancer history and outcomes in heart failure patients. It was found that heart failure patients with a history of cancer had a higher risk of hospitalization and non-cardiovascular death, but the risks of cardiovascular and all-cause death were similar. In heart failure patients with preserved ejection fraction, the presence or absence of cancer history did not affect the outcomes. The incidence of new cancer diagnoses was similar in both heart failure groups.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Ana Barat, Chien-Wei Chen, Natasha Patel-Murray, John J. V. McMurray, Milton Packer, Scott D. Solomon, Akshay S. Desai, Jean L. Rouleau, Michael R. Zile, Zenab Attari, Cong Zhang, Huilei Xu, Nicole Hartman, Claudia Hon, Margaret Healey, William Chutkow, Christopher J. O'Donnell, Jaison Jacob, Marty Lefkowitz, Michael M. Mendelson, Simon Wandel, Denise Yates, Claudio Gimpelewicz
Summary: This study aimed to evaluate the prevalence of pathogenic variants in genes associated with DCM in a population with heart failure and reduced ejection fraction (HFrEF) and describe the baseline characteristics by variant carrier status. The study analyzed data from the PARADIGM-HF trial and found that around 5% of HFrEF patients had deleterious pLoF variants in genes strongly associated with DCM. These carriers were younger, had lower ejection fraction, and were less likely to have an ischaemic etiology compared to non-carriers.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Editorial Material
Medicine, General & Internal
John J. V. McMurray, Marco Metra
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Jawad H. Butt, Kieran F. Docherty, Brian L. Claggett, Akshay S. Desai, Magnus Petersson, Anna Maria Langkilde, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Lars Kober, Carolyn S. P. Lam, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, Sanjiv J. Shah, Muthiah Vaduganathan, Pardeep S. Jhund, Scott D. Solomon, John J. V. McMurray
Summary: This study found that gout is common in patients with heart failure and sodium-glucose cotransporter 2 inhibitors can reduce uric acid levels. Gout was associated with worse clinical outcomes, but the efficacy of dapagliflozin was consistent in patients with and without gout. Dapagliflozin also reduced the initiation of new treatments for hyperuricemia and gout.
Article
Cardiac & Cardiovascular Systems
Alexander Peikert, Alvin Chandra, Mikhail N. Kosiborod, Brian L. Claggett, Akshay S. Desai, Pardeep S. Jhund, Carolyn S. P. Lam, Silvio E. Inzucchi, Felipe A. Martinez, Rudolf A. de Boer, Adrian F. Hernandez, Sanjiv J. Shah, Stefan P. Janssens, Jan Belohlavek, C. Jan Willem Borleffs, Dan Dobreanu, Anna Maria Langkilde, Olof Bengtsson, Magnus Petersson, John J. V. McMurray, Scott D. Solomon, Muthiah Vaduganathan
Summary: In this study, dapagliflozin was found to improve the overall health status of heart failure patients. The improvements were particularly significant in domains related to symptom frequency and physical limitations, which are more easily recognized and communicated to patients.
Editorial Material
Cardiac & Cardiovascular Systems
Joe J. Cuthbert, John G. F. Cleland
CARDIOVASCULAR RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Ankeet S. Bhatt, Mikhail N. Kosiborod, Brian L. Claggett, Zi Michael Miao, Muthiah Vaduganathan, Carolyn S. P. Lam, Adrian F. Hernandez, Felipe A. Martinez, Silvio E. Inzucchi, Sanjiv J. Shah, Rudolf A. de Boer, Pardeep S. Jhund, Akshay S. Desai, James C. Fang, Yaling Han, Josep Comin-Colet, Jaroslaw Drozdz, Orly Vardeny, Bela Merkely, Daniel Lindholm, Magnus Peterson, Anna Maria Langkilde, John J. V. McMurray, Scott D. Solomon
Summary: This study aimed to evaluate the association between COVID-19 and clinical outcomes in patients with chronic heart failure. The study found that COVID-19 was common among the participants, with over 50% of cases leading to hospitalization or death. COVID-19 diagnosis was significantly associated with an increased risk of death in the 12 months following diagnosis. Additionally, dapagliflozin showed treatment benefits in reducing cardiovascular death/worsening heart failure events.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Pascal. M. Burger, Gianluigi Savarese, Jasper Tromp, Carly Adamson, Pardeep. S. Jhund, Lina Benson, Camilla Hage, Wan Ting Tay, Scott. D. Solomon, Milton Packer, Xavier Rossello, John. W. McEvoy, Dirk De Bacquer, Adam Timmis, Panos Vardos, Lan. M. Graham, Emanuele Di Angelantonio, Frank L. J. Visseren, John. J. McMurray, Carolyn S. P. Lam, Lars. H. Lund, Stefan Koudstaal, Jannick A. N. Dorresteijn, Arend Mosterd
Summary: The LIFE-HF model is a tool for estimating lifelong survival and treatment benefit in HFrEF patients, which can improve the management of HFrEF and facilitate personalized medicine and shared decision-making.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Geriatrics & Gerontology
Mariam Elmegaard Malik, Jawad Haider Butt, Jarl Emanuel Strange, Alexander Christian Falkentoft, Jesper Jensen, Charlotte Andersson, Deewa Zahir, Emil Fosbol, Mark C. Petrie, Naveed Sattar, John J. McMurray, Lars Kober, Morten Schou
Summary: This study examined the impact of frailty on the initiation of SGLT2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease. It was found that frail patients had a significantly lower probability of initiating these two drug therapies, indicating the need for clear guidelines for their use in this population.
LANCET HEALTHY LONGEVITY
(2023)
Letter
Medicine, General & Internal
Nathalie Conrad, John J. V. McMurray
Article
Urology & Nephrology
Sunil Bhandari, Patrick Parfrey, Claire D. White, Stefan Anker, Kenneth Farrington, Ian A. Ford, Philip Kalra, John J. V. McMurray, Michele Robertson, Charles R. V. C. Tomson, David C. Wheeler, Iain Macdougall
Summary: This study analyzed the baseline quality of life measures in participants from the PIVOTAL trial and found that quality of life was impaired in patients starting hemodialysis. A higher C-reactive protein level was consistently associated with worse quality of life. Transferrin saturation was also found to be a predictor of worse physical component score of quality of life.
JOURNAL OF NEPHROLOGY
(2023)